biote Corp. (NASDAQ:BTMD) CFO Robert Charles Peterson Sells 11,376 Shares of Stock

biote Corp. (NASDAQ:BTMD) CFO Robert Charles Peterson sold 11,376 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $7.57, for a total transaction of $86,116.32. Following the completion of the sale, the chief financial officer now directly owns 32,874 shares in the company, valued at approximately $248,856.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

biote Stock Performance

NASDAQ BTMD opened at $7.80 on Thursday. The company has a fifty day simple moving average of $6.60 and a 200 day simple moving average of $5.68. The company has a market cap of $483.91 million, a P/E ratio of 70.91 and a beta of 0.98. biote Corp. has a 12-month low of $3.65 and a 12-month high of $8.22.

biote (NASDAQ:BTMD) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.18. The business had revenue of $46.80 million for the quarter, compared to analysts’ expectations of $47.09 million. biote had a negative return on equity of 36.67% and a net margin of 4.30%. Sell-side analysts predict that biote Corp. will post 0.56 EPS for the current year.

Hedge Funds Weigh In On biote

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of biote during the fourth quarter valued at about $53,000. Bailard Inc. purchased a new stake in shares of biote during the 4th quarter valued at $96,000. SW Investment Management LLC lifted its stake in biote by 3.5% during the fourth quarter. SW Investment Management LLC now owns 675,000 shares of the company’s stock worth $3,334,000 after purchasing an additional 22,651 shares during the last quarter. Finally, Bandera Partners LLC lifted its position in biote by 7.5% in the 4th quarter. Bandera Partners LLC now owns 1,832,732 shares of the company’s stock worth $9,054,000 after buying an additional 127,410 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Roth Mkm reiterated a “buy” rating and set a $9.00 price target (up from $8.00) on shares of biote in a report on Wednesday, March 13th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $8.11.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.